Maurice was pacing his trading floor perch, half-eaten banana in one hand, a printout of FDA approval letters in the other, muttering about the backwards magic of modern biotech markets.
You know that feeling when you’ve been waiting months for something magnificent to happen, it finally does, and everyone responds by throwing things at you? That’s Rocket Pharmaceuticals this week. And I’ve spent the last three days trying to figure out if the market is genius or if we’re all collectively having a breakdown.
Let me back up. Rocket Pharmaceuticals (RCKT) just got FDA accelerated approval for KRESLADI, their lead gene therapy candidate for severe LAD-I—Leukocyte Adhesion Deficiency-I, a rare immunodeficiency disorder that sounds like something from a medical thriller and works like your immune system forgot to show up to work. This is exactly the kind of inflection point Foxy’s thesis was built around. This is the moment. This is the big swing. And the stock has tanked nearly 9% since the announcement.
I threw a banana at my monitor. It stuck. I’m choosing to interpret that as a sign.
The Setup That Almost Made Sense
Three weeks ago, Foxy handed me this stock with a conviction level that made even my skeptical monkey brain sit up straight. A late-stage biotech—we’re talking companies that have moved past the “we think this might work” stage and into the “we’re literally testing it on humans” stage—with a gene therapy platform. Low debt-to-equity ratio. Stable, low beta (0.574, which means it doesn’t thrash around like a caffeinated capuchin). And a pipeline supposedly approaching regulatory inflection points.
On paper, it was the kind of setup that makes sense: a company with multiple shots on goal, rare disease focus (which means less competition, more desperate patients, higher prices), and approaching catalysts that could unlock massive value in an undercapitalized corner of biotech.
The entry was supposed to be around $4.68. The target price? $9.50. That’s roughly double. In biotech, if you can point to a reasonable path to double, investors usually listen.
But we’re trading at $3.64 as I write this, which means the stock has already slipped down the banana peel before we even got the big news.
The Paradox That Broke My Brain
Here’s what happened: Rocket got exactly what it needed. FDA accelerated approval for KRESLADI. This is not small. This is not a “promising preliminary data” kind of thing. This is “we have a drug. It’s approved. You can sell it now.” The approval came for a pediatric indication—severe LAD-I in children—where the disease is devastating, treatment options are nonexistent, and families would frankly consider selling their houses for a working cure.
And yet, the market responded by punching the stock in the face.
Why? Let me articulate the three theories I’ve been testing:
Theory One: The Market Pricing in Commercial Reality
LAD-I is rare. We’re talking genuinely rare—maybe a few hundred cases total in the United States. Maybe. Gene therapies are expensive, typically running $2-3 million per patient for initial treatment, though that can come down with volume. You do the math: even if Rocket captures the entire LAD-I market globally, we’re talking peak annual revenues in the hundreds of millions, not billions. That doesn’t support a $2-3 billion valuation. Maybe it supports $400-600 million in peak sales. And that’s if everything goes perfectly.
The market might be saying: “Yes, you got an approval. No, it doesn’t matter much for the stock price, because the patient population is too small.”
Theory Two: The Pipeline Anxiety Play
KRESLADI is one banana in a fruit bowl. Rocket has other programs—Danon disease (RP-A501), cardiac indications like PKP2-ACM and BAG3-DCM—but those are further back in development. Danon is in Phase 2. The cardiac programs are Phase 1 or preclinical. One approval doesn’t de-risk the whole pipeline. One approval shows the platform works. One approval is also the easiest test case they’ll ever run.
As someone who watches small biotech companies die regularly, I can tell you: one approval from a tiny company doesn’t automatically mean the rest of the pipeline will succeed. Different patients. Different tissues. Different challenges. The market might be pricing in the sobering reality that most biotech programs fail, even when one succeeds.
Theory Three: The Short Squeeze That Wasn’t
Look at that short ratio: 4.64. That’s elevated. That means 4.64 days worth of average volume is shorted. When a stock this small gets good news, shorts often panic-cover, creating a squeeze. But RCKT didn’t squeeze. The shorts held. Or they’re smarter than I gave them credit for. Or they’re doing what shorts do: looking at the fundamental math and deciding one approval for one rare disease doesn’t change the fact that this company is burning cash at a remarkable rate.
Free cash flow: negative $104 million annually. They’re losing money hand over fist. The approval is great, but it doesn’t turn off the cash-burn spigot overnight.
The Thing That Actually Interests Me
Here’s where I stop throwing bananas and start thinking like someone who actually gives a damn about investing.
The market’s reaction, while frustrating for anyone who bought at $4.68, might actually be revealing something true: Rocket is undercapitalized, under-resourced, and operating in one of the most expensive businesses on Earth with a balance sheet that wouldn’t pass a mild stress test.
But—and this is a big, important, slightly-chaotic-monkey but—they now have an approved product. That changes everything for a company like this. Not because KRESLADI will make them rich. It won’t. But because they can now use that approval to:
One: Actually generate revenue. Even from a tiny population, revenue is revenue. It’s not going to be hundreds of millions immediately, but it moves the needle from “pure R&D burn” to “we have commercial traction.”
Two: Negotiate better financing deals. Banks and investors love approved products. The risk profile just dropped. A company with an approved rare disease gene therapy can raise capital on better terms than a company with only pipeline hopes.
Three: Partner or M&A upside. A company with one approved gene therapy and a three-program pipeline becomes interesting to larger pharma companies thinking about gene therapy platforms. They might not be a home run acquisition target, but they’re definitely on someone’s radar now.
The Reality Check I’m Not Ignoring
I need to be honest here, and honesty is something I save for when I’m eating my favorite bananas.
The entry point Foxy recommended ($4.68) is already behind us. The stock has actually performed worse than the broader market since that recommendation. We’re currently 22% below entry. That’s not catastrophic, but it’s not encouraging. The analysts are split (11 covering this stock, a decent number for a micro-cap biotech), and the target prices vary wildly from below $4 to as high as $12.
The debt-to-equity ratio of 8.974 is genuinely concerning. That’s not “a little leveraged.” That’s “if things go wrong, the balance sheet gets blown up.” They have $104 million in negative free cash flow annually. At current cash burn rates, they can run for maybe 2-3 years before needing a capital raise, even with the KRESLADI revenues coming in.
The market cap is $395 million. The share price has bounced between $2.19 and $8.26 over the last year. That’s not confidence. That’s not stability. That’s a stock that investors genuinely don’t know how to price.
And here’s the thing that keeps me up at night: gene therapy is controversial in some quarters. There are regulatory concerns. There are manufacturing concerns. There are long-term follow-up questions. One approval is not a validation that the entire field is proven.
The Three-Year Projection That Makes My Brain Hurt
If I’m really generous to Rocket, here’s what could happen by 2028-2029:
KRESLADI generates maybe $150-250 million in annual peak sales. The Danon program (RP-A501) advances through Phase 2, shows positive data, maybe gets approval or partnership by 2028. The cardiac programs advance one step forward. A larger pharma company becomes interested. Rocket either partners with someone (good outcome) or gets acquired (neutral outcome) or successfully navigates to profitability on their own (unlikely outcome).
In that scenario, a $9.50 stock price is plausible. Maybe even conservative if the partnerships go well.
But that’s the generous version. The realistic version includes: regulatory setbacks, manufacturing challenges, slower-than-expected patient uptake for a $2-3 million gene therapy, competitors entering the space, another cash raise that dilutes shareholders, and the possibility that their other programs just… don’t work.
That’s the world we actually live in.
The Maurice Verdict
I’m genuinely torn on Rocket. And not because I’m indecisive. I’m torn because it’s legitimately a coin flip dressed up as due diligence.
The bull case is real: approved product, de-risked platform, rare disease focus with pricing power, and multiple shots on goal. The company went from “we hope this works” to “it works and we’re selling it” in the span of a week. That matters.
But the bear case is also real: tiny addressable market, massive cash burn, concerning debt levels, unproven commercial execution, and a pipeline where the success rate is almost certainly below 50%.
Foxy’s recommendation had 8/10 confidence, and I understand why. This is exactly the kind of setup where undercapitalized biotech companies with one approval become acquisition targets or successful commercial stories. It happens. But it also doesn’t happen more often than it does.
The market’s reaction—down 9% on FDA approval—tells me something: the market thinks this approval is already priced in, or the market thinks the approval doesn’t matter much for a company with this burn rate. I’m inclined to think the market is right on the second point.
That doesn’t mean don’t own it. That means own it with your eyes open, with position sizing that reflects the risk, and with a time horizon of at least 3-5 years. Don’t own it expecting to double quickly. Own it hoping you’re right about one of their other programs or hoping the right acquisition partner comes calling.
And maybe—just maybe—I’m wrong, KRESLADI becomes a bigger commercial story than anyone expects, their next program crushes it, and we look back at $3.64 as the steal of the decade.
But you know what bananas teach you? Even the best bananas sometimes go brown faster than you expect.
Trained Market Monkey 